WO2009041501A1 - ヘルペスウイルスの潜伏感染に関与する因子及びその利用 - Google Patents

ヘルペスウイルスの潜伏感染に関与する因子及びその利用 Download PDF

Info

Publication number
WO2009041501A1
WO2009041501A1 PCT/JP2008/067300 JP2008067300W WO2009041501A1 WO 2009041501 A1 WO2009041501 A1 WO 2009041501A1 JP 2008067300 W JP2008067300 W JP 2008067300W WO 2009041501 A1 WO2009041501 A1 WO 2009041501A1
Authority
WO
WIPO (PCT)
Prior art keywords
herpesvirus
latent infection
disorder
factor involved
mental
Prior art date
Application number
PCT/JP2008/067300
Other languages
English (en)
French (fr)
Inventor
Kazuhiro Kondo
Nobuyuki Kobayashi
Original Assignee
Virus Ikagaku Kenkyusho Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ584642A priority Critical patent/NZ584642A/xx
Priority to MX2010003318A priority patent/MX2010003318A/es
Application filed by Virus Ikagaku Kenkyusho Inc. filed Critical Virus Ikagaku Kenkyusho Inc.
Priority to US12/679,816 priority patent/US8431352B2/en
Priority to CN200880108759.4A priority patent/CN101809153B/zh
Priority to JP2009534359A priority patent/JP4920084B2/ja
Priority to EP08833887.6A priority patent/EP2199391B1/en
Priority to UAA201005063A priority patent/UA101814C2/ru
Priority to EP15187953.3A priority patent/EP2987859B1/en
Priority to AU2008304896A priority patent/AU2008304896B9/en
Priority to ES08833887.6T priority patent/ES2554340T3/es
Priority to EA201070400A priority patent/EA023557B1/ru
Priority to CA2701668A priority patent/CA2701668C/en
Publication of WO2009041501A1 publication Critical patent/WO2009041501A1/ja
Priority to IL204641A priority patent/IL204641A/en
Priority to ZA2010/02424A priority patent/ZA201002424B/en
Priority to IL219541A priority patent/IL219541A0/en
Priority to US13/732,981 priority patent/US20130217044A1/en
Priority to US13/756,858 priority patent/US10526374B2/en
Priority to US15/462,031 priority patent/US10487118B2/en
Priority to US16/688,650 priority patent/US20200071363A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16511—Roseolovirus, e.g. human herpesvirus 6, 7
    • C12N2710/16522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16511—Roseolovirus, e.g. human herpesvirus 6, 7
    • C12N2710/16571—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/035—Herpes simplex virus I or II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Abstract

　本発明に係るタンパク質及び遺伝子は、ヘルペスウイルスの潜伏感染に関与する因子である。精神障害患者の約５０％に該因子に対する抗体が検出される一方、健常者ではほとんど検出されない。また、ＳＩＴＨ－１を導入したマウスは、躁うつ病やうつ病様の精神障害を示した。このため、この事実に基づき、精神障害を客観的に判定し得る方法および精神障害モデル動物を提供することができる。
PCT/JP2008/067300 2007-09-27 2008-09-25 ヘルペスウイルスの潜伏感染に関与する因子及びその利用 WO2009041501A1 (ja)

Priority Applications (19)

Application Number Priority Date Filing Date Title
EA201070400A EA023557B1 (ru) 2007-09-27 2008-09-25 Белок, вовлеченный в латентную инфекцию герпесвирусом, и его применение для диагностики ментальных нарушений у животных
ES08833887.6T ES2554340T3 (es) 2007-09-27 2008-09-25 Factor implicado en la infección latente por herpesvirus, y su uso
CA2701668A CA2701668C (en) 2007-09-27 2008-09-25 Factor involved in latent infection with herpesvirus, and use thereof
MX2010003318A MX2010003318A (es) 2007-09-27 2008-09-25 Factor involucrado en la infeccion latente con herpesvirus y su uso.
JP2009534359A JP4920084B2 (ja) 2007-09-27 2008-09-25 ヘルペスウイルスの潜伏感染に関与する因子及びその利用
EP08833887.6A EP2199391B1 (en) 2007-09-27 2008-09-25 Factor involved in latent infection with herpesvirus, and use thereof
UAA201005063A UA101814C2 (ru) 2007-09-27 2008-09-25 Фактор, задействованный в латентной инфекции герпесвирусом, и его применение
EP15187953.3A EP2987859B1 (en) 2007-09-27 2008-09-25 Factor involved in latent infection with herpesvirus, and use thereof
AU2008304896A AU2008304896B9 (en) 2007-09-27 2008-09-25 Factor involved in latent infection with herpesvirus, and use thereof
NZ584642A NZ584642A (en) 2007-09-27 2008-09-25 Factor involved in latent infection with herpesvirus, and use thereof
CN200880108759.4A CN101809153B (zh) 2007-09-27 2008-09-25 参与疱疹病毒的潜伏感染的因子及其利用
US12/679,816 US8431352B2 (en) 2007-09-27 2008-09-25 Diagnosis of mood disorders by detecting latent infection with human herpesvirus-6
IL204641A IL204641A (en) 2007-09-27 2010-03-21 METHOD FOR DETERMINING THE ANTI-ANTI-PRACTICE ANTIGIN FOR THE LEGENDIC CYCLOPYLIN
ZA2010/02424A ZA201002424B (en) 2007-09-27 2010-04-07 Factor involved in latent infection with herpesvirus,and use thereof
IL219541A IL219541A0 (en) 2007-09-27 2012-05-02 Factor involved in latent infection with herpesvirus, and use thereof
US13/732,981 US20130217044A1 (en) 2007-09-27 2013-01-02 Factor involved in latent infection with herpesvirus, and use thereof
US13/756,858 US10526374B2 (en) 2007-09-27 2013-02-01 Factor involved in latent infection with herpesvirus, and use thereof
US15/462,031 US10487118B2 (en) 2007-09-27 2017-03-17 Factor involved in latent infection with herpes virus, and use thereof
US16/688,650 US20200071363A1 (en) 2007-09-27 2019-11-19 Animal model of a mood disorder and screening method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-250461 2007-09-27
JP2007250461 2007-09-27

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/679,816 A-371-Of-International US8431352B2 (en) 2007-09-27 2008-09-25 Diagnosis of mood disorders by detecting latent infection with human herpesvirus-6
US13/732,981 Division US20130217044A1 (en) 2007-09-27 2013-01-02 Factor involved in latent infection with herpesvirus, and use thereof
US13/756,858 Division US10526374B2 (en) 2007-09-27 2013-02-01 Factor involved in latent infection with herpesvirus, and use thereof

Publications (1)

Publication Number Publication Date
WO2009041501A1 true WO2009041501A1 (ja) 2009-04-02

Family

ID=40511384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/067300 WO2009041501A1 (ja) 2007-09-27 2008-09-25 ヘルペスウイルスの潜伏感染に関与する因子及びその利用

Country Status (15)

Country Link
US (5) US8431352B2 (ja)
EP (2) EP2199391B1 (ja)
JP (4) JP4920084B2 (ja)
KR (1) KR101655486B1 (ja)
CN (1) CN101809153B (ja)
AU (1) AU2008304896B9 (ja)
CA (1) CA2701668C (ja)
EA (1) EA023557B1 (ja)
ES (1) ES2554340T3 (ja)
IL (2) IL204641A (ja)
MX (1) MX2010003318A (ja)
NZ (2) NZ584642A (ja)
UA (1) UA101814C2 (ja)
WO (1) WO2009041501A1 (ja)
ZA (1) ZA201002424B (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114029A1 (ja) * 2009-03-31 2010-10-07 日本たばこ産業株式会社 生物学的試料中のｓｉｔｈ－１の抗体を検出する方法
JPWO2010114031A1 (ja) * 2009-03-31 2012-10-11 日本たばこ産業株式会社 生物学的試料中の物質を検出する方法
WO2016031581A1 (ja) * 2014-08-27 2016-03-03 株式会社ウイルス医科学研究所 疲労に関与する因子及びその利用
WO2017115878A1 (ja) 2015-12-28 2017-07-06 日本たばこ産業株式会社 気分障害を診断、治療又は予防する方法
US10487118B2 (en) 2007-09-27 2019-11-26 Virus Ikagaku Kenkyusho Inc. Factor involved in latent infection with herpes virus, and use thereof
WO2020202923A1 (ja) 2019-03-29 2020-10-08 日本たばこ産業株式会社 うつ病の評価方法及びうつ病の治療法の効果の評価方法、並びにうつ病若しくはうつ病の治療法の効果を評価するためのデータ取得方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657324B1 (en) 2008-10-03 2017-05-23 Virus Ikagaku Kenkyusho Inc. Method for treating or preventing mood disorders
EP3058105B1 (en) * 2013-10-18 2019-05-22 Seegene, Inc. Detection of target nucleic acid sequence on solid phase by pto cleavage and extension using hcto assay
EP3163301B1 (en) * 2014-06-27 2019-08-07 Japan Tobacco, Inc. Method for treating, or preventing mood disorder
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
CN109376816B (zh) * 2018-09-11 2022-04-01 广州金域医学检验中心有限公司 一种病理切片质量监控方法及其装置

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US823975A (en) 1905-08-07 1906-06-19 Harry B Smith Device for filling fountain-pens.
EP0171496A2 (en) 1984-08-15 1986-02-19 Research Development Corporation of Japan Process for the production of a chimera monoclonal antibody
EP0173494A2 (en) 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by DNA splicing and expression
WO1986001533A1 (en) 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
EP0232262A1 (en) 1985-08-15 1987-08-19 Stauffer Chemical Company Tryptophan producing microorganism
US4708781A (en) 1985-10-18 1987-11-24 Andromaque, S.A. Process of simultaneously printing and electroforming ceramic articles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2045869A1 (en) 1990-06-28 1991-12-29 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US5908746A (en) 1995-06-09 1999-06-01 Nisshinbo Industries, Inc. Method for analyzing biologically active substances

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901857A1 (de) 1989-01-23 1990-07-26 Boehringer Mannheim Gmbh Verfahren zur bestimmung von hiv 2 antikoerpern
GB9303157D0 (en) 1993-02-17 1993-03-31 Scotia Holdings Plc Treatment of a group of related disorders
JP3206311B2 (ja) 1994-07-29 2001-09-10 富士レビオ株式会社 抗体検出用試薬の非特異反応吸収剤
JPH11196870A (ja) 1998-01-08 1999-07-27 Katsuhiko Mikoshiba 受容体の機能解析法及びリガンド分子のスクリーニング法
CA2477675C (en) 2002-03-05 2013-05-21 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein
EP1572946B1 (en) 2002-09-06 2012-03-14 Amgen, Inc. Therapeutic human anti-il-1r1 monoclonal antibody
JP2004301646A (ja) 2003-03-31 2004-10-28 Sysmex Corp 免疫検査用非特異反応吸収剤
EP1681346A4 (en) 2003-08-29 2006-11-02 Soiken Inc HHV-6 OR HHV-7 DERIVED RECOMBINANT VIRUS VECTOR, METHOD FOR THE PRODUCTION THEREOF, METHOD FOR TRANSFORMING A HOST CELL USING THEREOF, TRANSFORMED HOST CELL AND GENE THERAPY METHOD USING THEREOF
JP4218842B2 (ja) 2004-07-14 2009-02-04 株式会社ウイルス医科学研究所 疲労度評価方法およびその利用
US20090068253A1 (en) 2005-09-06 2009-03-12 Guilford F Timothy Method for the treatment of infection with hhv-6 virus and the amelioration of symptoms related to virus using liposomal encapsulation for delivery of reduced glutathione
US20080176340A1 (en) 2006-11-01 2008-07-24 Beckman Coulter, Inc. Binding surfaces for affinity assays
EP1978365B1 (en) 2007-03-16 2010-08-25 Sysmex Corporation Reagent kit and method for measuring HCV antibody
JP4975601B2 (ja) 2007-03-16 2012-07-11 シスメックス株式会社 Ｈｃｖ抗体測定用試薬キット及びｈｃｖ抗体測定方法
US7972804B2 (en) 2007-07-03 2011-07-05 One Lambda Methods of detecting antibodies specific for denatured HLA antigens
EP2184356A4 (en) 2007-08-28 2012-02-22 Japan Tobacco Inc METHOD FOR BONDING PROTEIN TO MEDIA USING TAMAVIDINE
CA2701668C (en) 2007-09-27 2017-07-11 Virus Ikagaku Kenkyusho Inc. Factor involved in latent infection with herpesvirus, and use thereof
WO2009123347A1 (ja) 2008-03-31 2009-10-08 日本たばこ産業株式会社 ウイルス定量法
WO2009155379A2 (en) 2008-06-17 2009-12-23 Hhv-6 Foundation Artemisinin and derivatives thereof as antivirals
CA2753873A1 (en) 2009-03-02 2010-09-10 Japan Tobacco Inc. Method for detecting substance in biological sample
RU2011143788A (ru) 2009-03-31 2013-05-10 Джапан Тобакко Инк. Способ детектирования анти-sith-1 антитела в биологическом образце
US9034590B2 (en) 2009-03-31 2015-05-19 Japan Tobacco Inc. Method for detecting substance in biological sample
JP2013150553A (ja) 2012-01-24 2013-08-08 Osaka Bioscience Institute ＣａｒｔｐｔｍＲＮＡ発現細胞標識動物およびそれを用いたスクリーニング方法
JP2014019658A (ja) 2012-07-13 2014-02-03 Hiroshima Univ 抗−ｓ９７７リン酸化ｐｅｒ２特異的抗体
EP3163301B1 (en) 2014-06-27 2019-08-07 Japan Tobacco, Inc. Method for treating, or preventing mood disorder

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US823975A (en) 1905-08-07 1906-06-19 Harry B Smith Device for filling fountain-pens.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0171496A2 (en) 1984-08-15 1986-02-19 Research Development Corporation of Japan Process for the production of a chimera monoclonal antibody
EP0173494A2 (en) 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by DNA splicing and expression
WO1986001533A1 (en) 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
EP0232262A1 (en) 1985-08-15 1987-08-19 Stauffer Chemical Company Tryptophan producing microorganism
US4708781A (en) 1985-10-18 1987-11-24 Andromaque, S.A. Process of simultaneously printing and electroforming ceramic articles
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
CA2045869A1 (en) 1990-06-28 1991-12-29 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
EP0464533A1 (de) 1990-06-28 1992-01-08 BEHRINGWERKE Aktiengesellschaft Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
US5908746A (en) 1995-06-09 1999-06-01 Nisshinbo Industries, Inc. Method for analyzing biologically active substances
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
"The Radiochemical Detection of Cancer", 1982, MASSON PUBLISHING INC.
BITTLE, F. J. ET AL., J. GEN. VIROL., vol. 66, 1985, pages 2347 - 2354
BOULIANNE ET AL., NATURE, vol. 312, 1984, pages 643
CARASQUILLO ET AL., J. NUCL. MED., vol. 28, 1987, pages 281 - 287
CELL, vol. 88, 1997, pages 243
CHOW, M. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, pages 910 - 914
D. BENNETT ET AL., JOURNAL OF MOLECULAR RECOGNITION, vol. 8, 1995, pages 52 - 58
DOMINGUEZ,G. ET AL.: "Human herpesvirus 6B genome sequence: coding content and comparison with human herpesvirus 6A", J. VIROL., vol. 73, no. 10, 1999, pages 8040 - 8052 *
ESTEBAN ET AL., J. NUCL. MED., vol. 28, 1987, pages 861 - 870
GENTZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 821 - 824
GEYSEN, H. M. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 3998 - 4002
HARLOW ET AL.: "Antibodies: A laboratory manual", 1988, COLD SPRING HARBOR LABORATORY
HASHIMOTO-GOTOH, GENE, vol. 152, 1995, pages 271 - 275
IACOBELLI ET AL., BREAST CANCER RESEARCH AND TREATMENT, vol. 11, 1988, pages 19 - 30
IWASAKI ET AL.: "Tankurohn koutai haiburidoma to ELISA", MONOCLONAL ANTIBODY HYBRIDOMAS AND ELISA, 1991
J. SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY
K. JOHANSON ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 16, 1995, pages 9459 - 9471
KAZUHIRO KONDO ET AL.: "Shinkei Shikkan Oyobi Shokaki Shikkan no Kiin Virus no Kaimei", TOKUTEI SHIKKAN NO BISEIBUTSUGAKUTEKI GEN'IN KYUMEI NI KANSURU KENKYU, 2006.03, HEISEI 17 NENDO SOKATSU.BUNTAN KENKYU HOKOKUSHO, March 2006 (2006-03-01), pages 19 - 23, XP008142313 *
KAZUHIRO KONDO ET AL.: "Shinkei Shikkan Oyobi Shokaki Shikkan no Kiin Virus no Kaimei", TOKUTEI SHIKKAN NO BISEIBUTSUGAKUTEKI GEN'IN KYUMEI NI KANSURU KENKYU, 2007.03, HEISEI 18 NENDO SOKATSU·BUNTAN KENKYU HOKOKUSHO, March 2007 (2007-03-01), pages 13 - 18, XP008142311 *
KAZUHIRO KONDO ET AL.: "Shinkei Shikkan Oyobi Shokaki Shikkan no Kiin Virus no Kaimei", TOKUTEI SHIKKAN NO BISEIBUTSUGAKUTEKI GEN'IN KYUMEI NI KANSURU KENKYU, 2008.03, HEISEI 19 NENDO SOKATSU.BUNTAN KENKYU HOKOKUSHO, March 2008 (2008-03-01), pages 17 - 23, XP008142314 *
KAZUHIRO KONDO: "Herpesvirus Kansen to Hiro (Herpesvirus latency and fatigue)", VIRUS, vol. 55, no. 1, 2005, pages 9 - 18
KAZUHIRO KONDO: "Herpesvirus Kansen to Hiro", VIRUS, vol. 55, no. 1, 2005, pages 9 - 18, XP008123498 *
KAZUHIRO KONDO: "Hito Herpesvirus 6 (HHV-6) to CFS", PROG.MED., vol. 25, 2005, pages 1315 - 1319, XP001539884 *
KAZUHIRO KONDO: "Virus no Senpuku Kansen Tanpakushitsu to Hiro", MOLECULAR MEDICINE, vol. 41, no. 10, 2004, pages 1216 - 1221, XP002997729 *
KENNEDY ET AL., CLIN. CHIM. ACTA, vol. 70, 1976, pages 1 - 31
KONDO K ET AL.: "Recognition of a Novel Stage of Beta-Herpesvirus Latency in Human Herpesvirus 6", J VIROL., vol. 77, 2003, pages 2258 - 2264
KONDO K. ET AL.: "Identification of human herpesvirus 6 latency-associated transcripts", J. VIROL., vol. 76, no. 8, 2002, pages 4145 - 4151, XP003009785 *
KONDO K. ET AL.: "Recognition of a novel stage of betaherpesvirus latency in human herpesvirus 6", J. VIROL., vol. 77, no. 3, 2003, pages 2258 - 2264, XP008123390 *
KONDO. K ET AL.: "Association of human herpesvirus 6 infection of the central nervous system with recurrence of febrile convulsions", J INFECT DIS, vol. 167, 1993, pages 1197 - 1200
KONDO. K ET AL.: "Identification of human herpesvirus 6 latency-associated transcripts", J VIROL., vol. 76, 2002, pages 4145 - 4151
KONDO. K ET AL.: "Ltatent human herpesvirus 6 infection of human monocytes /macrophages", J GEN VIROL, vol. 72, 1991, pages 1401 - 1408
MANIATIS, T. ET AL.: "Molecular Cloning A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
MORRISON, SCIENCE, vol. 229, 1985, pages 1202
NATURE, vol. 389, 1997, pages 300
NEUBERGER ET AL., NATURE, vol. 314, 1985, pages 268
NOBUYUKI KOBAYASHI ET AL.: "Hito Herpesvirus (HHV)-6 Senpuku Kansen Tokuiteki Tanpaku ni yoru Utsu Shojo no Hassho Kijo", DAI 55 KAI THE JAPANESE SOCIETY OF VIROLOGY GAKUJUTSU SHUKAI PROGRAM. SHOROKUSHU, 1 October 2007 (2007-10-01), pages 120, XP008124718 *
OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214
PERKINS ET AL., EUR. J. NUCL. MED., vol. 10, 1985, pages 296 - 301
S. W. BURCHIEL ET AL.: "Tumer Imaging", article "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments"
SCHURS ET AL., CLIN. CHIM. ACTA, vol. 81, 1977, pages 1 - 40
SCIENCE, vol. 270, 1995, pages 484
SCIENCE, vol. 276, 1997, pages 1268
See also references of EP2199391A4
VERMA ET AL.: "Human Chromosomes: a Manual of Basic Techniques", 1988, PERGAMON PRESS
WAHL ET AL., J. NUCL. MED., vol. 24, 1983, pages 316 - 325
WILSON ET AL., CELL, vol. 37, 1984, pages 767
WILSON, I. A. ET AL., CELL, vol. 37, 1984, pages 767 - 778

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10487118B2 (en) 2007-09-27 2019-11-26 Virus Ikagaku Kenkyusho Inc. Factor involved in latent infection with herpes virus, and use thereof
EP2416159A1 (en) * 2009-03-31 2012-02-08 Japan Tobacco, Inc. Method for detecting antibody against sith-1 in biological sample
CN102449483A (zh) * 2009-03-31 2012-05-09 日本烟草产业株式会社 对生物学样品中的sith-1抗体进行检测的方法
EP2416159A4 (en) * 2009-03-31 2012-05-30 Japan Tobacco Inc METHOD FOR DETECTING ANTIBODY AGAINST SITH-1 IN A BIOLOGICAL SAMPLE
JPWO2010114031A1 (ja) * 2009-03-31 2012-10-11 日本たばこ産業株式会社 生物学的試料中の物質を検出する方法
JPWO2010114029A1 (ja) * 2009-03-31 2012-10-11 日本たばこ産業株式会社 生物学的試料中のｓｉｔｈ−１の抗体を検出する方法
JP5628793B2 (ja) * 2009-03-31 2014-11-19 日本たばこ産業株式会社 生物学的試料中の物質を検出する方法
US9139617B2 (en) 2009-03-31 2015-09-22 Japan Tobacco Inc. Method for detecting antibody against SITH-1 in biological sample
WO2010114029A1 (ja) * 2009-03-31 2010-10-07 日本たばこ産業株式会社 生物学的試料中のｓｉｔｈ－１の抗体を検出する方法
WO2016031581A1 (ja) * 2014-08-27 2016-03-03 株式会社ウイルス医科学研究所 疲労に関与する因子及びその利用
JPWO2016031581A1 (ja) * 2014-08-27 2017-06-08 株式会社ウイルス医科学研究所 疲労に関与する因子及びその利用
JP2020058355A (ja) * 2014-08-27 2020-04-16 株式会社ウイルス医科学研究所 疲労に関与する因子及びその利用
JP7033113B2 (ja) 2014-08-27 2022-03-09 株式会社ウイルス医科学研究所 疲労に関与する因子及びその利用
WO2017115878A1 (ja) 2015-12-28 2017-07-06 日本たばこ産業株式会社 気分障害を診断、治療又は予防する方法
JPWO2017115878A1 (ja) * 2015-12-28 2018-12-13 日本たばこ産業株式会社 気分障害を診断、治療又は予防する方法
EP3398969A4 (en) * 2015-12-28 2019-07-31 Japan Tobacco, Inc. METHOD FOR DIAGNOSING, TREATING OR PREVENTING MOOD DISORDERS
US10539578B2 (en) 2015-12-28 2020-01-21 Japan Tobacco Inc. Method for diagnosing, treating, or preventing mood disorders
WO2020202923A1 (ja) 2019-03-29 2020-10-08 日本たばこ産業株式会社 うつ病の評価方法及びうつ病の治療法の効果の評価方法、並びにうつ病若しくはうつ病の治療法の効果を評価するためのデータ取得方法

Also Published As

Publication number Publication date
UA101814C2 (ru) 2013-05-13
EP2199391B1 (en) 2015-11-11
NZ599590A (en) 2013-12-20
KR20100074191A (ko) 2010-07-01
EP2199391A4 (en) 2011-01-19
IL204641A0 (en) 2010-11-30
CN101809153B (zh) 2014-01-01
EA023557B1 (ru) 2016-06-30
US20200071363A1 (en) 2020-03-05
EP2987859A1 (en) 2016-02-24
CA2701668A1 (en) 2009-04-02
US8431352B2 (en) 2013-04-30
US10526374B2 (en) 2020-01-07
AU2008304896B9 (en) 2014-12-18
ES2554340T3 (es) 2015-12-18
JP5829228B2 (ja) 2015-12-09
KR101655486B1 (ko) 2016-09-07
JP2016006435A (ja) 2016-01-14
NZ584642A (en) 2012-08-31
AU2008304896A2 (en) 2010-05-27
IL204641A (en) 2013-08-29
JP2013188210A (ja) 2013-09-26
IL219541A0 (en) 2012-06-28
US20170190745A1 (en) 2017-07-06
CA2701668C (en) 2017-07-11
EA201070400A1 (ru) 2010-10-29
US10487118B2 (en) 2019-11-26
ZA201002424B (en) 2011-02-23
MX2010003318A (es) 2010-04-09
US20130137088A1 (en) 2013-05-30
JP4920084B2 (ja) 2012-04-18
US20130217044A1 (en) 2013-08-22
JP5337232B2 (ja) 2013-11-06
EP2987859B1 (en) 2018-08-08
AU2008304896A1 (en) 2009-04-02
EP2199391A1 (en) 2010-06-23
US20100281550A1 (en) 2010-11-04
CN101809153A (zh) 2010-08-18
AU2008304896B2 (en) 2014-07-31
JP2012110329A (ja) 2012-06-14
JPWO2009041501A1 (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
WO2009041501A1 (ja) ヘルペスウイルスの潜伏感染に関与する因子及びその利用
WO2009117122A3 (en) Genetic analysis
WO2007112397A3 (en) System and method of predicting efficacy of tongue-base therapies
WO2005079363A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
IL211140A (en) A method for determining the risk of Alzheimer's disease based on the presence or absence of changes in the tomm40 gene
DE602005020209D1 (de) System zur Evaluierung von Herzstörungen
WO2008070137A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2009063325A3 (en) Methods and systems for treating illnesses
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
WO2008137838A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2006088888A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2007120480A3 (en) Systems and methods for predicting effectiveness in the treatment of psychiatric disorders, including depression
WO2006002262A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2006093507A3 (en) Methods and systems for predicting cancer outcome
WO2009009330A3 (en) Methods, systems and devices for detecting and diagnosing heart diseases and disorders
WO2007067968A3 (en) Effects of inhibitors of fgfr3 on gene transcription
WO2006002437A3 (en) Treatment of conditions involving demyelination
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
WO2005079284A3 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
EP3784029A4 (en) TALEN-BASED AND CRISPR/CAS-BASED GENE EDITING FOR BRUTON'S TYROSINE KINASE
ATE525919T1 (de) Bouillon- oder würzkonzentrat und verfahren zu dessen herstellung
BRPI0920170A2 (pt) métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
WO2009027703A3 (en) Identifying organ damage
WO2008008487A3 (en) Gene expression profiling for identification, monitoring and treatment of multiple sclerosis
WO2010102160A3 (en) Diagnostic method using palb2

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880108759.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08833887

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12010500601

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 204641

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12679816

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2009534359

Country of ref document: JP

Ref document number: MX/A/2010/003318

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2701668

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107008198

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 584642

Country of ref document: NZ

Ref document number: 2157/CHENP/2010

Country of ref document: IN

Ref document number: 2008304896

Country of ref document: AU

Ref document number: 2008833887

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201070400

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PI 2010001229

Country of ref document: MY

ENP Entry into the national phase

Ref document number: 2008304896

Country of ref document: AU

Date of ref document: 20080925

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 219541

Country of ref document: IL

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0817046

Country of ref document: BR

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0817046

Country of ref document: BR